WSGR logoWSGR logo
Gopika Das Mesrobian
Associate
Technology Transactions
Boston

D857-507-1684

Download vCard
Open PDF

Gopika Das Mesrobian is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the technology transactions group and focuses on the life sciences, medical device, and biotech industries.

During law school, Gopika interned at the Rian Immigrant Center and the New England Innocence Project. Prior to attending law school, Gopika was a public health practitioner specializing in maternal and newborn health of displaced populations.

Experience

Gopika Das Mesrobian is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the technology transactions group and focuses on the life sciences, medical device, and biotech industries.

During law school, Gopika interned at the Rian Immigrant Center and the New England Innocence Project. Prior to attending law school, Gopika was a public health practitioner specializing in maternal and newborn health of displaced populations.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Learn More
Client Highlights
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.